A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major.
Cardiovascular disease resulting from iron accumulation is still a major cause of death in patients with thalassemia major (TM) Voltage gated calcium channel blockade prevents iron entry into cardiomyocytes and may provide an adjuvant treatment to chelation, reducing myocardial iron uptake. We evaluated whether addition of amlodipine to chelation strategies would reduce myocardial iron overload in TM patients compared with placebo. In a multicenter, double blind, randomized, placebo controlled trial, 62 patients were allocated to receive oral amlodipine 5 mg/day or placebo in addition to their current chelation regimen. The main outcome was change in myocardial iron concentration (MIC) determined by magnetic resonance imaging at 12 months, with patients stratified into reduction or prevention groups according to their initial T2* below or above the normal human threshold of 35 ms (MIC, 0.59 mg/g dry weight) At 12 months, patients in the reduction group receiving amlodipine (n 15) had a significant decrease in MIC compared with patients receiving placebo (n 15) with a median of 0.26 mg/g (95% confidence interval, 1.02 to 0.01) vs 0.01 mg/g (95% confidence interval, 0.13 to 0.23) P .02. No significant changes were observed in the prevention group (treatment effect interaction with P .005) The same findings were observed in the subgroup of patients with T2* <20 ms. Amlodipine treatment did not cause any serious adverse events. Thus, in TM patients with cardiac siderosis, amlodipine combined with chelation therapy reduced cardiac iron more effectively than chelation therapy alone. Because this conclusion is based on subgroup analyses, it needs to be confirmed in ad hoc clinical trials. This trial was registered at www.clinicaltrials.gov identifier as #NCT01395199.
Blood